The ZUMA-3 Study reveals a therapy called KTE-X19 appears safe and demonstrated encouraging efficacy as a treatment for patients with relapsed/refractory acute lymphoblastic leukemia reports an update from the study team at the 2019 ASCO Meeting.
The primary objective of the study was to determine the safety and efficacy of KTE-X19 in adult populations with relapsed/refractory (r/r) B-precursor acute lymphoblastic leukemia (ALL).
What is KTE-X19?
KTE-X19 is an investigational CD19 CAR T cell therapy. TGhe treatment has the same construct as axicabtagene ciloleucel; however, the manufacturing process for KTE-X19 differs from that of axicabtagene ciloleucel and includes the enrichment of lymphocytes. Lymphocyte enrichment is necessary for certain B-cell malignancies for which KTE-X19 is under investigation. The drug has been in clinical trials for acute lymphoblastic leukemia (ALL), mantel cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).
Who is Kite Pharma?
Kite Pharma, a Gilead company, is a biopharma venture operating in Santa Monica, CA. Kite is engaged in the development of innovative cancer immunotherapies. The company focuses on chimeric antigen receptor and T cell receptor engineered cell therapies.
Bijal Shah, MD and ZUMA-3 investigator and oncologist with the Moffit Cancer Center, Tampa, Flordia, noted: “Adults with relapsed or refractory ALL represent an extremely difficult-to-treat patient population.” Dr. Shah continued “We’re encouraged by the high response rates in this study, as well as the reduced incidence and severity of CRS and neurologic events that were observed following implementation of the revised safety management protocol. We are now evaluating the use of KTE-X19 at the selected dose with this safety management protocol in the ongoing ZUMA-3 Phase 2 study.”